Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Fr | Azitra, Inc. - S-1, General form for registration of securities | 3 | SEC Filings | ||
03.07. | Azitra, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
17.06. | Azitra, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
17.06. | Azitra, Inc.: Azitra Reports Promising Safety Data from Phase 1b Trial in Netherton Syndrome | 124 | PR Newswire | Drug candidate ATR12-351 has been generally safe and well-tolerated with occasional, transient, mild to moderate symptoms at application site
Trial is 50% enrolled... ► Artikel lesen | |
14.05. | Azitra GAAP EPS of -$0.23 | 1 | Seeking Alpha | ||
13.05. | Azitra, Inc. Announces Q1 2025 Results and Provides Business Updates | 118 | PR Newswire | BRANFORD, Conn., May 13, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative... ► Artikel lesen | |
AZITRA Aktie jetzt für 0€ handeln | |||||
13.05. | Azitra, Inc. - 8-K, Current Report | 11 | SEC Filings | ||
13.05. | Azitra, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
02.05. | Azitra, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
29.04. | Azitra, Inc. - S-1, General form for registration of securities | 3 | SEC Filings | ||
24.04. | Azitra, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
24.04. | Azitra secures funding deal for dermatology treatments | 1 | Investing.com | ||
24.04. | Azitra sichert Finanzierungsvereinbarung für Dermatologie-Behandlungen | 1 | Investing.com Deutsch | ||
26.02. | Maxim Group cuts Azitra stock price target to $2 from $3, retains Buy rating | 6 | Investing.com | ||
25.02. | Azitra reports FY results | 2 | Seeking Alpha | ||
24.02. | Azitra, Inc. Announces Full Year 2024 Financial Results and Provides Business Updates | 161 | PR Newswire | BRANFORD, Conn., Feb. 20, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative... ► Artikel lesen | |
24.02. | Azitra, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
20.02. | Azitra, Inc. - 8-K, Current Report | - | SEC Filings | ||
06.02. | Azitra, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
04.02. | Azitra announces pricing of $930,000 registered direct offering | 5 | Seeking Alpha |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 41,405 | -0,35 % | Dividendenbekanntmachungen (10.07.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACCENTURE PLC IE00B4BNMY34 1,48 USD 1,2626 EUR AT&T INC US00206R1023 0,2775 USD 0,2367 EUR AZZ INC US0024741045 0,2 USD 0,1706... ► Artikel lesen | |
NUVALENT | 83,40 | -2,67 % | Nuvalent, Inc.: Nuvalent Announces Positive Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC | Aligned with FDA on NDA submission strategy for TKI pre-treated patients with advanced ROS1-positive NSCLC and participation in Real-Time Oncology Review; the... ► Artikel lesen | |
IMMUNOVANT | 17,910 | -2,02 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 | Immunovant's new management team is focused on rapid clinical execution for the six announced indications for IMVT-1402, including a second potentially registrational study in Graves' disease (GD)... ► Artikel lesen | |
EVOTEC | 7,456 | +0,59 % | Bayer, NetraMark, Evotec: Wie KI-Forschung jetzt Renditen beschleunigt und Ihr Depot optimieren könnte | Die Gesundheitsbranche wird 2025 von KI und Technologien radikal umgekrempelt. Während Pharmariesen unter Kostendruck und regulatorischen Stürmen ächzen revolutionieren Algorithmen die Arzneimittelentwicklung:... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 5,845 | +5,89 % | Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth? | ||
SUMMIT THERAPEUTICS | 26,200 | -5,18 % | Summit Therapeutics (SMMT) Climbs 16% Ahead of Q2 Earnings | ||
BIONTECH | 94,40 | -2,13 % | DAX-Korrektur! BioTech Im Übernahme-Modus! BioNTech, CureVac, Pfizer, Vidac Pharma und Kraft Heinz im Fokus | Die Aktienmärkte zeigen sich in Bestform: Sowohl der DAX als auch der NASDAQ 100 haben in den vergangenen Tagen Muskeln gezeigt. Angetrieben werden die Kurse vor allem von der anhaltenden Stärke der... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 33,740 | -0,88 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD Participants | -- Unprecedented data from FORTITUDE dose escalation cohorts for del-brax treated participants, compared to placebo, demonstrate improvement in function, strength and PROs as well as rapid... ► Artikel lesen | |
ARVINAS | 7,350 | -5,34 % | Arvinas Inc.: Arvinas Announces Retirement of Chief Executive Officer and Succession Plan | - John Houston, Ph.D., Chairperson, CEO and President at Arvinas, Announces Plans to Retire as CEO Upon Appointment of Successor - - Dr. Houston to Remain Chairperson of Arvinas Board of Directors... ► Artikel lesen | |
TELOMIR PHARMACEUTICALS | 2,300 | +90,08 % | Telomir Pharmaceuticals, Inc: Telomir Demonstrates Telomir-1 Reverses Epigenetic Gene Silencing of STAT1, Restoring Tumor Suppressor in Human Prostate Cancer Cells, Outperforming Chemotherapy and Rapamycin | New data shows Telomir-1 fully reverses STAT1 gene silencing by DNA methylation - a key immune regulator suppressed in cancer - delivering stronger epigenetic effects than Paclitaxel or Rapamycin in... ► Artikel lesen | |
VERVE THERAPEUTICS | 10,915 | -0,32 % | Verve Therapeutics sichert Führungskräfte mit Halteprämien vor Übernahme durch Eli Lilly | ||
ADMA BIOLOGICS | 16,730 | -4,89 % | ADMA Biologics, Inc.: ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update | 1Q 2025 Total Revenue of $114.8 Million (Adjusted Total Revenue(1) of $118.6 Million), a 40% YoY Increase 1Q 2025 GAAP Net Income of $26.9 Million, a 51% YoY Increase 1Q 2025 Adjusted EBITDA(2) of... ► Artikel lesen | |
SAREPTA THERAPEUTICS | 12,080 | -0,29 % | Sarepta Therapeutics-Aktie +35%: Ist das die Wende? | Die Kursentwicklung der Sarepta Therapeutics -Aktie trieb Anlegern in jüngster Vergangenheit nur die Tränen in die Augen. In den letzten zwölf Monaten lösten sich fast -90% des Börsenwerts des Biotech-Unternehmens... ► Artikel lesen | |
COGENT BIOSCIENCES | 12,500 | +2,29 % | Cogent Biosciences auf Rekordhoch: Positive Studienergebnisse und Kapitalerhöhung beflügeln Kurs | ||
TARSUS PHARMACEUTICALS | 43,250 | +4,54 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements | Generated $78.3 million in net product sales of XDEMVY®, an increase of 217% year over year and 18% over Q4 2024, and dispensed approximately 72,000 bottles to patients Strengthened financial position... ► Artikel lesen |